
SXTP Stock Forecast & Price Target
SXTP Analyst Ratings
Bulls say
60 Degrees Pharmaceuticals Inc. has demonstrated significant growth in net product revenues, which surged by 140% to $607.6k in FY24, alongside a sequential revenue increase of 20% and a year-over-year growth of 145%. The consistent sales growth of ARAKODA, paired with tafenoquine’s favorable safety profile and potential for expanded clinical applications, underscores a promising trajectory for the company’s product pipeline. Furthermore, the rise in babesiosis cases, reported by the CDC, highlights an increasing market demand that could further enhance ARAKODA's commercialization opportunities.
Bears say
60 Degrees Pharmaceuticals Inc faces a negative outlook primarily due to a significant revenue decline, with product revenues dropping to $100,000, caused by supply constraints despite some offset from Australian research grant revenue. The company also suffers from low visibility on the ramp-up of revenue and potential regulatory approvals, contributing to pessimism regarding its financial trajectory. Additionally, concerns regarding cash burn and possible dilution from future financing exacerbate the risks associated with investing in the company.
This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
SXTP Analyst Forecast & Price Prediction
Start investing in SXTP
Order type
Buy in
Order amount
Est. shares
0 shares